Temelimab
What studies of temelimab found
At a glance, by condition
Long COVID: F Harms
Based on the strongest evidence, the placebo trial (low certainty): 3 findings, all F.
7 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found temelimab made things worse for long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- Temelimab · Long COVID is hereFHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Cognition (brain fog)1 study · 96 people received temelimab Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
No clear difference in cognition (brain fog).
The evidence is very uncertain about the effect of temelimab on cognition (brain fog) in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- Composite BAC score improvement relative risk brief assessment of cognition
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Fatigue1 study · 96 people received temelimab Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
No clear difference in fatigue.
The evidence is very uncertain about the effect of temelimab on fatigue in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- PROMIS Fatigue SF 7a score patient-reported outcomes measurement information system fatigue short form 7a
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Some concerns
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Anxiety1 study · 96 people received temelimab Worse F
Why this grade: Worse, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (203 in all).
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
Anxiety was worse with temelimab.
Temelimab may worsen anxiety in long COVID. Worse · low certainty F
- Some concerns about bias (RoB 2)
- Few people (203 in all)
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- GAD-7 generalized anxiety disorder (GAD 7)
- Effect
- worse
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Depression1 study · 96 people received temelimab Worse F
Why this grade: Worse, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (203 in all).
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
Depression was worse with temelimab.
Temelimab may worsen depression in long COVID. Worse · low certainty F
- Some concerns about bias (RoB 2)
- Few people (203 in all)
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- PHQ-9 patient health questionnaire (PHQ-9)
- Effect
- worse
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning1 study · 96 people received temelimab Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
No clear difference in daily functioning.
The evidence is very uncertain about the effect of temelimab on daily functioning in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- Sheehan Disability Scale [SDS] SDS
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Overall symptoms1 study · 96 people received temelimab Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 203 people found no clear difference; a small benefit can't be ruled out.
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of temelimab on overall symptoms in long COVID. Little or no difference · very low certainty D
- Some concerns about bias (RoB 2)
- One trial of 203 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- secondary outcomes overall
- Effect
- no clear difference
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Quality of life1 study · 96 people received temelimab Worse F
Why this grade: Worse, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (203 in all).
The placebo trial203 randomised · Week 24 · 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
Quality of life was worse with temelimab.
Temelimab may worsen quality of life in long COVID. Worse · low certainty F
- Some concerns about bias (RoB 2)
- Few people (203 in all)
See the 1 study
-
Temelimab versus placebo in patients with post-COVID condition. (2026)
- People in the study
- 203 randomised
- Dose
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks
- Outcome
- EQ5D-5L European quality of life 5-dimension-5-level (EQ5D-5L) scale
- Effect
- worse
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Low
- Deviations from intended interventions
- Low
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
54 mg at the start
- 2Top dose
Most often 54 mg (1 of 1 studies)
Doses across 1 study
54 to 54 mg.
Each study’s dose, as printed
- 54 mg/kg, once monthly / every 4 weeks for 6 IV infusions over 24 weeks Temelimab versus placebo in patients with post-COVID condition. (2026)
All papers
- Temelimab versus placebo in patients with post-COVID condition.2026 · placebo trial · 203 randomised
Summary
This randomized, double-blind, placebo-controlled, multicenter phase II trial enrolled 203 adults with post-COVID condition and positive HERV-W ENV at 14 centres in Switzerland, Italy, and Spain; 72% were women and mean age was 46 (SD 10). Participants received 54 mg/kg Temelimab or matching placebo intravenously once monthly for six infusions over 24 weeks, with current standard of care. The primary endpoint was a decrease of at least 3 points on the PROMIS Fatigue SF 7a scale from baseline to Week 24. At Week 24, a decrease of at least 3 points occurred in 47 of 96 Temelimab participants and 51 of 94 placebo participants. Mean PROMIS decrease was 3.2 points with Temelimab and 3.8 with placebo; the between-group difference was 0.62 (95% CI -0.78 to 2.01), and the relative risk was 0.9 (95% CI 0.6–1.2). Secondary outcomes also did not show differences between groups. No significant adverse events were reported, and there was no difference in adverse effects reported between groups. The authors state limitations including lack of an objective measurement in the primary outcome and power only for the primary outcome.